The global prevalence of dementia: a systematic review and metaanalysis
- PMID: 23305823
- DOI: 10.1016/j.jalz.2012.11.007
The global prevalence of dementia: a systematic review and metaanalysis
Abstract
Background: The evidence base on the prevalence of dementia is expanding rapidly, particularly in countries with low and middle incomes. A reappraisal of global prevalence and numbers is due, given the significant implications for social and public policy and planning.
Methods: In this study we provide a systematic review of the global literature on the prevalence of dementia (1980-2009) and metaanalysis to estimate the prevalence and numbers of those affected, aged ≥60 years in 21 Global Burden of Disease regions.
Results: Age-standardized prevalence for those aged ≥60 years varied in a narrow band, 5%-7% in most world regions, with a higher prevalence in Latin America (8.5%), and a distinctively lower prevalence in the four sub-Saharan African regions (2%-4%). It was estimated that 35.6 million people lived with dementia worldwide in 2010, with numbers expected to almost double every 20 years, to 65.7 million in 2030 and 115.4 million in 2050. In 2010, 58% of all people with dementia lived in countries with low or middle incomes, with this proportion anticipated to rise to 63% in 2030 and 71% in 2050.
Conclusion: The detailed estimates in this study constitute the best current basis for policymaking, planning, and allocation of health and welfare resources in dementia care. The age-specific prevalence of dementia varies little between world regions, and may converge further. Future projections of numbers of people with dementia may be modified substantially by preventive interventions (lowering incidence), improvements in treatment and care (prolonging survival), and disease-modifying interventions (preventing or slowing progression). All countries need to commission nationally representative surveys that are repeated regularly to monitor trends.
Copyright © 2013 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4. Cochrane Database Syst Rev. 2021. Update in: Cochrane Database Syst Rev. 2022 May 23;5:CD011535. doi: 10.1002/14651858.CD011535.pub5. PMID: 33871055 Free PMC article. Updated.
-
Sexual Harassment and Prevention Training.2024 Mar 29. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2024 Mar 29. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 36508513 Free Books & Documents.
-
Pharmacological interventions for those who have sexually offended or are at risk of offending.Cochrane Database Syst Rev. 2015 Feb 18;2015(2):CD007989. doi: 10.1002/14651858.CD007989.pub2. Cochrane Database Syst Rev. 2015. PMID: 25692326 Free PMC article.
-
How lived experiences of illness trajectories, burdens of treatment, and social inequalities shape service user and caregiver participation in health and social care: a theory-informed qualitative evidence synthesis.Health Soc Care Deliv Res. 2025 Jun;13(24):1-120. doi: 10.3310/HGTQ8159. Health Soc Care Deliv Res. 2025. PMID: 40548558
-
Interventions for preventing and reducing the use of physical restraints for older people in all long-term care settings.Cochrane Database Syst Rev. 2023 Jul 28;7(7):CD007546. doi: 10.1002/14651858.CD007546.pub3. Cochrane Database Syst Rev. 2023. PMID: 37500094 Free PMC article.
Cited by
-
Normative Data for the Montreal Cognitive Assessment in Middle-Aged and Elderly Quebec-French People.Arch Clin Neuropsychol. 2016 Nov 22;31(7):819-826. doi: 10.1093/arclin/acw076. Arch Clin Neuropsychol. 2016. PMID: 27625048 Free PMC article.
-
Biomarkers for dementia in Latin American countries: Gaps and opportunities.Alzheimers Dement. 2023 Feb;19(2):721-735. doi: 10.1002/alz.12757. Epub 2022 Sep 13. Alzheimers Dement. 2023. PMID: 36098676 Free PMC article.
-
Machine learning-based cognitive impairment classification with optimal combination of neuropsychological tests.Alzheimers Dement (N Y). 2020 Jul 19;6(1):e12049. doi: 10.1002/trc2.12049. eCollection 2020. Alzheimers Dement (N Y). 2020. PMID: 32699817 Free PMC article.
-
Salivary flow rate and the risk of cognitive impairment among Korean elders: a cross-sectional study.BMC Geriatr. 2021 Apr 14;21(1):245. doi: 10.1186/s12877-021-02200-2. BMC Geriatr. 2021. PMID: 33853530 Free PMC article.
-
Cardiovascular risk in subjects over 55 years of age and cognitive performance after five years. NEDICES2-RISK study. Study protocol.PLoS One. 2022 Nov 28;17(11):e0274589. doi: 10.1371/journal.pone.0274589. eCollection 2022. PLoS One. 2022. PMID: 36441718 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical